Proof of concept study towards development of personalized adjuvant (immuno)therapy in primary resectable pancreatic cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021742

Enrollment

Unknown

Registered

2019-03-07

Start date

2019-03-31

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal adenocarcinoma

Interventions

Gold Standard:The results of tumor cell enrichment in the source tumor xenograft model

Index test:laser&#32

capture&#32

microdissection&#32

and&#32

magnetic&#32

bead-based&#32

cell&#32

sorting

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalized patients diagnosed with primary resectable pancreatic ductal adenocarcinoma

Exclusion criteria

Exclusion criteria: Patients with (locally) advanced disease and/or distant metastasis detected intraoperatively were not included in the study

Design outcomes

Primary

Measure	Time frame
Degree of cell enrichment;	—

Countries

China

Contacts

Public ContactWU Heshui

Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

heshuiwu@hust.edu.cn+86 13720117761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026